Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study

BACKGROUND: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) should be considered for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) having estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m(2) and urine albumin-to-creatinine ratio (UACR) > 30 mg/g. However, SGL...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Su Jin, Lee, Seung Eun, Shin, Dong Hyun, Park, Ie Byung, Lee, Hui Seung, Kim, Kyoung-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122538/
https://www.ncbi.nlm.nih.gov/pubmed/33990175
http://dx.doi.org/10.1186/s12882-021-02381-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122538/
https://www.ncbi.nlm.nih.gov/pubmed/33990175
http://dx.doi.org/10.1186/s12882-021-02381-3

Ejemplares similares